Adults with atrial fibrillation with overweight or obesity were less likely to experience recurrent atrial arrhythmia when ...

The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

A widely prescribed diabetes drug may be sabotaging one of the most trusted strategies for preventing the disease: exercise.

An open-label study shows that patients who took metformin after catheter ablation for atrial fibrillation have significantly ...

Before the explosive popularity of GLP-1 weight loss drugs, another "wonder drug," metformin, has been at work lowering blood sugar levels for patients with Type 2 diabetes for decades, but scientists ...

A new research paper was published in Aging (listed as "Aging (Albany NY)" by MEDLINE/PubMed and "Aging-US" by Web of Science) Volume 15, Issue 3, entitled, "Metformin use history and genome-wide DNA ...

Recent research from Stanford University and Harvard Medical School (both MA, USA) has used a combination of mouse models, human blood samples and statistical analysis to reveal the mechanism behind ...

Rutgers scientists found that metformin can blunt many of the metabolic and cardiovascular improvements normally produced by ...

Rutgers researchers have discovered that a popular diabetes drug may reduce the health benefits people expect from it. A commonly prescribed medication for diabetes might actually be working against ...

Though Ozempic launched into the pop culture lexicon in late 2022, the drug, once known for its catchy commercial jingle, achieved Food & Drug Administration approval for A1C management in 2017.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today ...